<DOC>
	<DOCNO>NCT01674842</DOCNO>
	<brief_summary>This Phase I dose escalation study cisplatin concurrent radiation patient ER negative , PR negative HER2 negative breast cancer undergone breast-conserving surgery mastectomy . Primary objective : To assess safety , tolerability , maximum tolerate dose ( MTD ) cisplatin give concurrently radiation therapy participant Stage II III breast cancer undergone breast conserving surgery mastectomy</brief_summary>
	<brief_title>Cisplatin + RT Triple Negative Breast Cancer</brief_title>
	<detailed_description>This phase I dose escalation study cisplatin radiation determine toxicity combine treatment establish MTD .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Primary tumor triple negative breast cancer Breastconserving surgery mastectomy surgical excision gross disease negative surgical margin Pathologic clinical stage II III disease At least 3 week interval last chemotherapy administration/breast surgery radiation ( 8 week ) Pregnant breastfeed Prior radiation breast ipsilateral regional node Ongoing therapy investigational agent Hormonal therapy Significant comorbidity Pathologic complete response follow preoperative chemotherapy Biopsy proven metastatic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Triple negative</keyword>
	<keyword>Stage II</keyword>
	<keyword>Stage III</keyword>
</DOC>